Key Findings:  These results indicate that BCP acts via multiple neuroprotective mechanisms in our murine model and suggest that BCP may be viewed as a potential treatment and/or preventative agent for PD.
Type of Study:  Animal Study
Study Result:  Positive
Study Location(s):  Mexico, Spain, Switzerland
Year of Pub:  2017
Cannabinoids Studied:  AM-x Synthetic Cannabinoids
Terpenes Studied:  ß-Caryophyllene
Receptors Studied:  CB2
Ligands Studied:  Anti-inflammatory cytokines, Dopamine, Pro-inflammatory cytokines
Dosage: BCP (10 mg/kg, i.p. and 10 mg/kg through an oral gavage) for 5 consecutive days. The protective effect of BCP against astrocyte activation and microglia was fully reversed by pre-treating with 3 mg/kg AM630.
Route of Administration:  Injection, Oral (Ingestion)